The $7.80 central target is not an official published consensus; it is the arithmetic mean of nine individual analyst price targets collected from sources that identify the analyst, firm, target, and date. The targets reviewed were: H.C. Wainwright at $8 (October 1, 2026), Bank of America Securities at $8, Cantor Fitzgerald at $8, Oppenheimer at $9, Raymond James at $10, JonesTrading at $10, Citizens at $8, Evercore ISI at $6, and Chardan Capital at $3. The low-to-high range runs from $3.00 to $10.00, and every one of the nine ratings is a Buy or Strong Buy, with zero Hold or Sell ratings.
That unanimity masks meaningful disagreement. The spread reflects a fundamental debate about how much credit to give a platform that has only just produced its first human target-engagement data. Notably, several firms lowered targets through mid-2026: H.C. Wainwright cut from $12 to $8, Raymond James from $14 to $10, JonesTrading from $11 to $10, and Chardan from $4 to $3. These cuts were driven by execution, timeline, and regulatory-path concerns rather than a loss of confidence in the underlying science. Analysts generally cite the Axiomer validation, the NTCP franchise, and a catalyst-rich 2026–2027 roadmap as reasons for their Buy ratings.
ProQR Therapeutics N.V. is a clinical-stage RNA-editing biotechnology company based in Leiden, the Netherlands, and Cambridge, Massachusetts, listed on the Nasdaq. The shares traded near $1.34 in late October 2026, within a 52-week range of roughly $1.20 to $3.00 and well below the 50-day moving average near $1.82. Reaching $7.80 would require a rise of more than 480%—a move that, by any standard, is very large and is more typical of a biotech that successfully advances a candidate through late-stage trials than of a company still in early clinical development.
The plausible path is entirely data-driven. ProQR's Axiomer platform uses a cell's own ADAR (adenosine deaminase acting on RNA) machinery to make precise single-nucleotide edits to RNA. In June 2026, the company reported positive Phase 1 target-engagement data for AX-0810, its NTCP-targeting candidate for cholestatic liver diseases, marking the platform's first clinical validation. Follow-on data for AX-0810 and initial Phase 1 data for the next-generation AX-0811 are expected around year-end 2026, with biliary atresia data in the first half of 2027 and a potentially registration-enabling Phase 2 program targeted to begin in mid-2027. Meaningful progress on these milestones is what would have to occur for the stock to re-rate anywhere near the average target.
Several factors could support a move toward the target. First, the AX-0810 data showed an up to eight-fold increase in serum bile acids, exceeding the company's pre-defined threshold and providing evidence that the platform works in humans. Second, the balance sheet is comparatively strong for a company of this size: cash and equivalents of about €117.1 million as of June 30, 2026, plus a $59.2 million June financing that included a private placement with Eli Lilly, fund operations into mid-2028. Third, the pipeline is broadening, with AX-0422 for MPS I Hurler syndrome and AX-2911 for MASH (metabolic dysfunction-associated steatohepatitis) advancing toward the clinic, alongside an AI-enabled discovery engine and a partnership with Ginkgo Bioworks. A catalyst-rich 2027 could support a higher valuation if data continue to validate the platform.
The obstacles are substantial. ProQR has no approved products and generates no meaningful product revenue, so its valuation rests almost entirely on unproven early-stage data. Clinical-stage biotechs face binary risk: disappointing safety, efficacy, or enrollment data could sharply de-rate the shares. The company has already raised equity in 2026, and further dilution is likely as development costs mount. The stock has also fallen more than 50% over the past year and sits near its 52-week low, indicating weak investor sentiment and limited momentum. Finally, the wide $3-to-$10 analyst range itself signals genuine uncertainty about whether the platform's promise translates into commercial value.
Technically, the shares are in a long-term downtrend, trading near the $1.20 area that marks the 52-week low and a key support level. A durable resistance level sits near the prior 52-week high of roughly $3.00, with the 50-day moving average near $1.82 acting as an intermediate hurdle. A sustained move above $3.00 would be needed to signal a structural shift in trend, while a breakdown below $1.20 would open the door to new lows. The $7.80 target remains far above any established technical resistance, underscoring that reaching it depends on fundamental re-rating rather than chart momentum.
Analyst price targets generally reflect a research horizon of around 12 months, though individual firms may apply different timelines. Key items to monitor include the full AX-0810 Phase 1 dataset and initial AX-0811 data expected by year-end 2026, the company's next quarterly results and any update to cash-runway guidance, the biliary atresia investigator-initiated trial data in the first half of 2027, and any news from the Eli Lilly collaboration, including potential milestone payments. Changes in analyst targets following these data readouts will be an important signal of shifting conviction.
Investors tracking volatile, catalyst-driven names like ProQR may also monitor automated tools. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening alone. Explore the signals to complement your own research and stay responsive to rapid changes in market structure.
Can PRQR reach $7.80? The target—an average of nine analyst price targets ranging from $3 to $10—sits more than 480% above the recent price, making it a very large ask for a clinical-stage company with no approved products. The bull case rests on genuine scientific progress: first clinical validation of the Axiomer platform, a healthy cash runway into mid-2028, and a Lilly partnership. The bear case centers on binary clinical risk, ongoing dilution, a downtrending stock near its 52-week low, and the fact that analysts themselves have been cutting targets. Neither the average target nor any single target is a guarantee. The trajectory will hinge on the year-end 2026 data readouts and the company's ability to advance its NTCP franchise into registrational studies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PRQR has been loosely correlated with FRMM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if PRQR jumps, then FRMM could also see price increases.
| Ticker / NAME | Correlation To PRQR | 1D Price Change % | ||
|---|---|---|---|---|
| PRQR | 100% | +2.92% | ||
| FRMM - PRQR | 44% Loosely correlated | +2.62% | ||
| VIR - PRQR | 43% Loosely correlated | +4.90% | ||
| ENVB - PRQR | 43% Loosely correlated | -2.00% | ||
| WHWK - PRQR | 42% Loosely correlated | +2.26% | ||
| TSHA - PRQR | 41% Loosely correlated | +6.60% | ||
More | ||||